APA (7th ed.) Citation

A, S., L, V., Y, F., N, B. R., A, B., B, M., . . . B, N. (2025). Finite-course ocrelizumab in relapsing multiple sclerosis: Results of two prospective open-label trials with matched controls. Multiple sclerosis (Houndmills, Basingstoke, England), 31(11), 1338. https://doi.org/10.1177/13524585251375350

Chicago Style (17th ed.) Citation

A, Salazar-Camelo, et al. "Finite-course Ocrelizumab in Relapsing Multiple Sclerosis: Results of Two Prospective Open-label Trials with Matched Controls." Multiple Sclerosis (Houndmills, Basingstoke, England) 31, no. 11 (2025): 1338. https://doi.org/10.1177/13524585251375350.

MLA (9th ed.) Citation

A, Salazar-Camelo, et al. "Finite-course Ocrelizumab in Relapsing Multiple Sclerosis: Results of Two Prospective Open-label Trials with Matched Controls." Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 31, no. 11, 2025, p. 1338, https://doi.org/10.1177/13524585251375350.